Does family history tell me whether I will get vitiligo - or what it will do?
No. Vitiligo can run in families, but its inheritance is complex. Family history is useful context for a clinician. It does not confirm a diagnosis. Nor does it predict a person’s course. It also does not mean another family member will necessarily develop it. Evidence
Why this matters
- Sources cited, not yet graded
People I have heard from ask whether a parent passed this on, and whether a child will get it. I read MedlinePlus Genetics, which describes contributions from multiple genes. It also points to immune and environmental factors. A clinician may ask about vitiligo in close relatives. They may also ask about other autoimmune conditions there. That history can add context to the assessment.
Considerations
- Depends on you
The sources I read do not identify one “vitiligo gene.” They do not offer a routine predictive genetic test. They also do not calculate an individual family member’s future. A remembered family pattern may also be incomplete. It may also be based on an uncertain diagnosis.
Questions for your clinician
Which parts of my family history are relevant to this assessment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would any part of that history change what you examine or follow?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does vitiligo mean I have another autoimmune condition?
No. Vitiligo is autoimmune. Some other autoimmune conditions occur more often among people with vitiligo. But an association does not diagnose another condition. It does not mean that every person will develop one. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The patient resources I read treat personal symptoms as relevant context. So does the clinical guidance. They also treat personal history of autoimmune disease as relevant context. They treat family history of autoimmune disease the same way. Autoimmune thyroid disease is one association. It is the one those documents emphasize most consistently, so it is the one I follow here.
Considerations
- Depends on you
Group-level associations cannot show whether a particular symptom has an autoimmune cause. A long list of possible conditions exists. It is not a self-screening tool. Vitiligo does not explain every new health concern.
Questions for your clinician
My family history includes ___. Does that call for a separate evaluation?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which concerns belong with dermatology, primary care, or another clinician?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Why does thyroid health come up in a vitiligo appointment?
Autoimmune thyroid disease is a well-recognized association with vitiligo. A UK clinical guideline recommends thyroid testing. The US patient resource used here describes selected blood tests. These are a possible part of evaluation. It does not publish a thyroid-specific schedule. What applies to you is decided with your own care team. Evidence Evidence
Why this matters
- Sources cited, not yet graded
I read the British dermatology guideline, which recommends thyroid testing. This applies to people with vitiligo. I checked the NIAMS resource as well. It is US patient education, not a US screening guideline. It describes selected blood tests for associated autoimmune disease. These are one possible part of evaluation.
Considerations
- Depends on you
Vitiligo on its own is not a thyroid diagnosis. Which test, if any, is appropriate is your clinician’s call. The applicable guideline can change the clinician’s approach. So can age, symptoms, history, prior results, and care setting.
Questions for your clinician
Does the guidance you follow recommend thyroid evaluation for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What question would a test answer, and who would follow up the result?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Can vitiligo involve hair or mucous membranes?
Yes. Hair in an affected area can lose pigment. Vitiligo can also involve mucous membranes, such as the lips. Those changes still need clinical context. They should not be self-diagnosed from color alone. Evidence
Why this matters
- Sources cited, not yet graded
I read MedlinePlus Genetics, which describes premature whitening of hair. It also describes loss of color in mucous membranes. That includes the tissue that lines the lips. These are pigment changes. Hair whitening is not the same as hair loss.
Considerations
- Depends on you
A pale area or white hair does not establish its cause. Nor does it establish its subtype, activity, or severity. Photographs may miss clinically important details in mucosal areas.
Questions for your clinician
Is the hair or mucosal change part of the same diagnosis?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Do you need to examine more before naming it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
When might a clinician consider further evaluation?
Further evaluation may enter the conversation when a specific question arises. That question may come from the history, symptoms, or examination. It may also come from personal or family autoimmune history. Ask what the next step is for. It should not be a fixed panel for everyone. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Vitiligo assessment begins with history and examination. I checked NIAMS, which describes selected blood tests, an eye examination, or a biopsy. These are possible parts of evaluation. None of them are automatic. The clinical guidance I read also considers relevant comorbidity and differential diagnosis.
Considerations
- Depends on you
More testing is not automatically a better evaluation. A symptom and a result are questions for the clinician. So is how quickly you need care. That clinician knows your history and has examined you.
Questions for your clinician
What specific question would this test or referral answer?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would change based on the result?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If we do not investigate now, what would make you reconsider?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Who and what do these sources describe?
I read US patient education for this. I read a UK clinical guideline. I read international expert recommendations. They describe group-level evidence and clinical practice. They do not predict an individual diagnosis or future condition. Nor do they predict a correct testing plan. Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The sources I read agree on one thing. Broader personal and family health context can matter. The clinical documents are written for professional care. The patient resources summarize rather than reproduce the underlying evidence.
Considerations
- Depends on you
Guidelines can differ by jurisdiction, health system, and evidence-review date. They can also differ by expert judgment. People with atypical presentations may not be fully represented. I may not capture them fully here. Neither may people with multiple autoimmune conditions. The same is true for people with age-specific concerns.
Questions for your clinician
Which guideline applies in my care setting?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does my age, history, or presentation fall outside the groups described here?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- People I have heard from ask whether a parent passed this on, and whether a child will get it. I read MedlinePlus Genetics, which describes contributions from multiple genes. It also points to immune and environmental factors. A clinician may ask about vitiligo in close relatives. They may also ask about other autoimmune conditions there. That history can add context to the assessment.
- What it does not establish
- The sources I read do not identify one “vitiligo gene.” They do not offer a routine predictive genetic test. They also do not calculate an individual family member’s future. A remembered family pattern may also be incomplete. It may also be based on an uncertain diagnosis.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- MedlinePlus Genetics, National Library of MedicinePatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context on complex genetic susceptibility, family occurrence, associated autoimmune conditions, and possible pigment loss in hair and mucous membranes.
What it does not support
It does not predict inheritance or disease course for an individual, recommend genetic testing, diagnose a comorbidity, or prescribe a screening plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.